AppTech Payments Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AppTech Payments Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.40M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $276.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $504.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $450.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $354 | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $329.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $256.1K | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | $253.8K | Mar 30, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $771.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $224.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $317.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $230.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $204 | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $189.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $154.5K | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | $145.4K | Mar 30, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.92M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($8.93M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($18.51M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.28M) | Apr 1, 2024 |
| FY2021 | Dec 31, 2021 | ($79.25M) | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($4.19M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.34M) | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | ($2.51M) | Mar 30, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.58M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.55M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($19.19M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.23M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $77.3K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($3.61M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($948.4K) | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | ($2.05M) | Mar 30, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.35M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.98M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.50M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.56M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $169 | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $49.3K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $82.1K | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | $279.7K | Mar 30, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.00M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.79M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.87M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.00M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $8.4K | Mar 20, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.89M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($7.46M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($8.86M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($8.20M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.8K) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($591.4K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($760.5K) | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | ($192.8K) | Mar 30, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.39M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $8.99M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.52M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.6K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $379.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $84.9K | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | $31.2K | Mar 30, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.50M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.52M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.16M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.10M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.5K | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $8.57M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $7.53M | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | $7.08M | Mar 30, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.89M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.47M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $4.19M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $7.42M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $44.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($8.2K) | Mar 20, 2023 |
| FY2021 | Dec 31, 2019 | ($7.45M) | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | ($7.05M) | Mar 30, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.96M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.16M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.16M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($176.62M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($168.70M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($159.75M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($140.47M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($124.2K) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($44.95M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($40.76M) | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | ($39.42M) | Mar 30, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.5K | Mar 20, 2023 |
| FY2022 | Dec 31, 2021 | $8 | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $57.5K | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $24.2K | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $1.4K | Apr 30, 2021 |
| FY2019 | Dec 31, 2017 | $26.3K | Mar 30, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $67.4K | Apr 30, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 40.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 33.28M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 22.25M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 16.70M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 11.94M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | 9.32M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 84.15M | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | 86.80M | Mar 30, 2020 |